



MARK
CORPORATE ADVISORS

September 06, 2024

MCAPL: MUM: 2024-25: 0139

To,
The Listing Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400 001

Dear Sir/Madam,

Sub : Submission of Post Offer Advertisement

Ref : Open Offer to the Public Shareholders of Oxygenta Pharmaceutical Limited (“OPL”/“Target Company”)

With reference to the above referred Open Offer we have carried out the Post Offer Advertisement today in terms of Regulation 18 (12) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and subsequent amendments thereto (“SEBI (SAST) Regulations, 2011”), in all the newspapers where the Detailed Public Statement (“DPS”) was published.

As required under SEBI (SAST) Regulations, 2011, a Post-Offer Advertisement has been published in the following newspapers:

Sr. No.	Newspapers	Language	Editions
1)	Business Standard	English	All Editions
2)	Business Standard	Hindi	All Editions
3)	Navshakti	Marathi	Mumbai Edition
4)	Nava Telangana	Telugu	Hyderabad Edition

We are enclosing herewith a copy of the newspaper clipping of the Post Offer Advertisement published in Business Standard (English).

Kindly take the above information on your record and disseminate the Post Offer Advertisement on the website of BSE.

For Mark Corporate Advisors Private Limited



Manish Gaur
Asst. Vice-President

Encl: As Above.

MARK CORPORATE ADVISORS PVT. LTD.

CIN No : U67190MH2008PTC181996

GSTIN/UIN : 27AAF5379J1ZY

404/1, The Summit Business Bay, Sant Janabai Road, (Service Lane), Off. W. E. Highway, Vile Parle (E), Mumbai - 400 057
Tele : +91 22 2612 3207 Fax : +91 22 2612 3208 Web : www.markcorporateadvisors.com E-mail : info@markcorporateadvisors.com

OXYGENTA PHARMACEUTICAL LIMITED

(CIN: L24110TG1990PLC012038)

Registered Office: Survey No. 252/1, Aroor Village, Sadasivapet Mandal, Medak, Telangana-502 291.
Tel. No.: +91 84552 50080 | Email ID: cs@oxygentapharma.com | Website: www.oxygentapharma.com

Open Offer for acquisition up to 96,16,000 fully paid-up equity shares having face value of ₹10 each representing 26.00% of the Emerging Voting Share Capital of Oxygenta Pharmaceutical Limited ("OPL"/"Target Company") at a price of ₹16.00 per equity share from the eligible equity shareholders of the Target Company by Mr. M V S Prasad Reddy (alias Mr. Mallu Venkata Siva Prasad Reddy) ("Acquirer") pursuant to and in compliance with Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and amendments thereto ("SEBI (SAST) Regulations, 2011").

This Post Offer Advertisement is issued by Mark Corporate Advisors Private Limited ("Manager to the Offer"), in respect of the Open Offer, on behalf of the Acquirer pursuant to and in compliance with Regulation 18 (12) of SEBI (SAST) Regulations, 2011. The Detailed Public Statement with respect to the aforementioned offer was made on Thursday, April 18, 2024 in the following newspapers:

Sr. No.	Newspaper	Language	Edition(s)
1)	Business Standard	English	All Editions
2)	Business Standard	Hindi	All Editions
3)	Navshakti	Marathi	Mumbai Edition
4)	Nava Telangana	Telugu	Hyderabad Edition

1)	Name of the Target Company	:	Oxygenta Pharmaceutical Limited
2)	Name of the Acquirers	:	Mr. M V S Prasad Reddy : Acquirer (alias Mr. Mallu Venkata Siva Prasad Reddy)
3)	Name of the Manager to the Offer	:	Mark Corporate Advisors Private Limited
4)	Name of the Registrar to the Offer	:	Venture Capital and Corporate Investments Private Limited
5)	Offer Details:		
	a) Date of Opening of the Offer	:	Thursday, August 08, 2024
	b) Date of Closure of the Offer	:	Thursday, August 22, 2024
6)	Date of Completion of Payment of Consideration and communication of Rejection/Acceptance	:	Friday, August 30, 2024

7) Details of Acquisition by the Acquirer:

Sr. No.	Particulars	Proposed in the Letter of Offer ⁽¹⁾	Actuals ⁽¹⁾
7.1	Offer Price (in ₹)	₹16.00 per Equity Share	₹16.00 per Equity Share
7.2	Aggregate number of Shares tendered	Up to 96,16,000 Equity Shares ⁽²⁾	302 Equity Shares
7.3	Aggregate number of Shares accepted	Up to 96,16,000 Equity Shares ⁽²⁾	302 Equity Shares
7.4	Size of the Offer (Number of Equity Shares multiplied by Offer Price per Equity Share)	₹15,38,56,000 ⁽³⁾	₹4,832 ⁽³⁾
7.5	Shareholding of the Acquirer before Public Announcement		
	• Number	Nil	Nil
	• % of Emerging Voting Share Capital	Not Applicable	Not Applicable
7.6	Shares acquired by way of Share Purchase Agreement, Memorandum of Understanding and Preferential Allotment		
	• Number	94,52,600 ⁽⁴⁾	94,52,600 ⁽⁴⁾
	• % of Emerging Voting Share Capital	25.56%	25.56%
7.7	Shares Acquired by way of Open Offer		
	• Number	96,16,000 ⁽²⁾	302
	• % of Emerging Voting Share Capital	26.00%	Negligible%
7.8	Shares acquired after Detailed Public Statement ("DPS")		
	• Number	Nil	Nil
	• % of Emerging Voting Share Capital	Not Applicable	Not Applicable
	• Price of the Shares acquired	Not Applicable	Not Applicable
7.9	Post Offer Shareholding of the Acquirer		
	• Number	1,90,68,600 ⁽⁵⁾	94,52,902 ⁽⁵⁾
	• % of Emerging Voting Share Capital	51.56%	25.56%
7.10	Pre & Post offer Shareholding of the Public:		
		Pre-Offer	Post Offer
	• Number	1,80,77,600	84,61,600 ⁽²⁾
	• % of Emerging Voting Share Capital	48.88%	22.88%
		Pre-Offer	Post Offer
		48.88%	48.88%

⁽¹⁾ Percentages disclosed in the table above are computed on the basis of Emerging Voting Capital.

⁽²⁾ Assuming full acceptance in the Open Offer.

⁽³⁾ Excludes Brokerage and other charges.

⁽⁴⁾ 8,00,000 equity shares to be acquired by the Acquirer from the Promoter Seller of the Target Company pursuant to Share Purchase Agreement entered on April 08, 2024, 69,52,600 equity shares to be acquired by the Acquirer from the Non-Promoter Seller of the Target Company pursuant to an Memorandum of Understanding and 17,00,000 Equity Shares allotted to the Acquirer pursuant to the Board Meeting of the Target Company held on April 08, 2024 and shareholders' approval received on May 09, 2024. Further, it excludes 2,00,000 equity shares allotted to Amigos Molecular Solutions Private Limited and 1,00,000 equity shares allotted to Mrs. Rachamalla Aparna (Deemed PACs to the Acquirer).

⁽⁵⁾ Excluding (i) 3,00,000 equity shares representing 0.81% of the Emerging Voting Share Capital (2,00,000 equity shares to Amigos Molecular Solutions Private Limited and 1,00,000 equity shares to Mrs. Rachamalla Aparna) allotted to Deemed PACs to the Acquirer pursuant to Preferential Issue for which the Board Meeting was held on April 08, 2024 and shareholders' approval was received on May 09, 2024; and (ii) 91,53,300 equity shares held by the existing Promoter/Promoter Group of the Target Company representing 24.75% of the Emerging Voting Share Capital.

8) The Acquirer accepts full responsibility for the information contained in this Post Offer Advertisement and also for the obligations under SEBI (SAST) Regulations, 2011.

9) A copy of this Post Offer Advertisement will be available on the websites of SEBI and BSE Limited and will be dispatched to the registered office of the Target Company.

Capitalized terms used in this advertisement, but not defined herein, shall have the same meanings assigned to such terms in the Letter of Offer dated July 27, 2024.

Issued by Manager to the Offer:



MARK CORPORATE ADVISORS PRIVATE LIMITED
CIN: U67190MH2008PTC181996
404/1, The Summit Business Bay, Sant Janabai Road (Service Lane),
Off W. E. Highway, Vile Parle (East), Mumbai-400 057
Tel. No.: +91 22 2612 3207/08
Contact Person: Mr. Manish Gaur
E-Mail: openoffer@markcorporateadvisors.com
Investor Grievance Email ID: investorgrievance@markcorporateadvisors.com
SEBI Regn No.: INM000012128

For and on behalf of the Acquirer:
Sd/-

M V S Prasad Reddy
("Acquirer")

Date : September 06, 2024
Place : Tirupati